drugset / Trial / NCT05885386
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the effectiveness oftemozolomide in the neoadjuvant therapy oflocally advanced,or unresectable pheochromocytoma or paragangliom(PPGL). Temozolomide (TMZ) is a novel oral alkylation chemotherapeutic agent. Inthisstudy,temozolomidewill be used preoperatively in order to change unresectable tumors to resectable and reduce the high risk of surgery.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |